{"id":508187,"date":"2020-09-23T19:26:02","date_gmt":"2020-09-23T19:26:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=508187"},"modified":"2020-09-23T19:26:02","modified_gmt":"2020-09-23T19:26:02","slug":"acromegaly-competitive-analysis-pipeline-insights-key-pharma-players-and-emerging-therapies-2020-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acromegaly-competitive-analysis-pipeline-insights-key-pharma-players-and-emerging-therapies-2020-by-delveinsight_508187.html","title":{"rendered":"Acromegaly: Competitive Analysis, Pipeline Insights, Key Pharma Players and Emerging Therapies 2020 by DelveInsight"},"content":{"rendered":"
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n
“Acromegaly Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acromegaly market. A detailed picture of the Acromegaly pipeline landscape is provided, which includes the disease overview and Acromegaly treatment guidelines.<\/p>\n<\/div>\n

DelveInsight<\/strong> launched a new report on Acromegaly Pipeline Insight, 2020<\/a><\/strong>.<\/p>\n

Acromegaly is a hormonal disorder that results from the availability of excessive growth hormone (GH) in the body, which is produced by the pituitary gland (a small gland in the brain). In acromegaly, the pituitary produces an immoderate amount of GH, which is resulted from benign or noncancerous tumors on the pituitary. These benign tumors are called Adenomas.<\/p>\n

The symptoms in acromegaly vary from patient to patient. It can lead to unusual physical features, such as swollen hands and feet, deformities, and complications, with an impact also on muscle strength and bone health.<\/p>\n

“Acromegaly Pipeline Insight, 2020<\/strong>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acromegaly market. A detailed picture of the Acromegaly pipeline landscape is provided, which includes the disease overview and Acromegaly treatment guidelines.<\/p>\n

The assessment part of the report embraces in-depth Acromegaly commercial assessment and clinical assessment of the Acromegaly pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acromegaly collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

View report: <\/strong>https:\/\/www.delveinsight.com\/sample-request\/acromegaly-pipeline-insight<\/a><\/strong><\/p>\n

“The total number of prevalent cases of Acromegaly in 2017 were found to be 61,022 in the 7MM.”<\/strong><\/p>\n

The key players in Acromegaly market are:<\/strong>
1. Chiasma Pharma
2. Antisense Therapeutics
3. Crinetics Pharmaceuticals
4. Camurus
5. Pharmaspur
6. Ionis Pharmaceuticals
7. Strongbridge Biopharma
8. Midatech
9. Ipsen
10. Dauntless Pharmaceuticals
11. Ono Pharmaceuticals
And many others<\/p>\n

The launch of the emerging therapies is expected to significantly impact the Acromegaly treatment scenario in the upcoming years:-<\/strong>
Drugs covered<\/strong>
1. Octreotide capsules
2. Lanreotide PRF
3. Veldoreotide
4. CAM2029
5. CRN00808
6. IONIS-GHR-LRx
And many others<\/p>\n

Request for sample pages: <\/strong>https:\/\/www.delveinsight.com\/sample-request\/acromegaly-pipeline-insight<\/a><\/strong><\/p>\n

Pipeline Development Activities: ACROMEGALY
<\/strong>The report provides insights into:
1. All of the companies that are developing therapies for the treatment of Acromegaly with aggregate therapies developed by each company for the same.
2. Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Acromegaly treatment.
3. Acromegaly key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
4. Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
5. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Acromegaly market.<\/p>\n

Scope of the report:
<\/strong>1. The Acromegaly report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products<\/em> by development stage, product type, route of administration, molecule type, and MOA type for <\/em>Acromegaly across the complete product development cycle, including all clinical and nonclinical stages.
2. It comprises of detailed profiles of <\/em>Acromegaly therapeutic products<\/em> with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
3. Detailed Acromegaly research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.
4. Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across Acromegaly.<\/p>\n

Table of contents:
<\/strong>1. Report Introduction
2. Acromegaly
3. Acromegaly Current Treatment Patterns
4. Acromegaly – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Acromegaly Late Stage Products (Phase-III)
7. Acromegaly Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acromegaly Discontinued Products
13. Acromegaly Product Profiles
14. Acromegaly Key Companies
15. Acromegaly Key Products
16. Dormant and Discontinued Products
17. Acromegaly Unmet Needs
18. Acromegaly Future Perspectives
19. Acromegaly Analyst Review
20. Appendix
21. Report Methodology<\/p>\n

Download a full report: <\/strong>https:\/\/www.delveinsight.com\/sample-request\/acromegaly-pipeline-insight<\/a><\/strong><\/p>\n

Contact us:<\/strong><\/p>\n

Shruti Thakur
<\/strong>info@delveinsight.com
<\/strong>+91-9650213330
<\/strong>https:\/\/www.delveinsight.com\/<\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP “Acromegaly Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acromegaly market. A detailed picture of the Acromegaly pipeline landscape is provided, which includes the disease … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-508187","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/508187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=508187"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/508187\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=508187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=508187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=508187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}